Tirzepatide: A Comprehensive Clinical and Pharmacological Monograph

Executive Summary

Tirzepatide represents a paradigm shift in the management of type 2 diabetes mellitus (T2DM) and chronic weight management, establishing a new therapeutic class as the first-in-class, unimolecular dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.[1] Developed by Eli Lilly and Company, this synthetic 39-amino acid peptide, marketed as Mounjaro® for T2DM and Zepbound® for chronic weight management and obstructive sleep apnea (OSA), has demonstrated unprecedented efficacy in both glycemic control and weight reduction across a comprehensive suite of clinical trials.[3] Its unique "twincretin" mechanism of action leverages the synergistic effects of two key incretin hormones to provide metabolic benefits that surpass those of selective GLP-1 receptor agonists (RAs), the previous therapeutic benchmark.[5]

The landmark SURPASS clinical trial program, which evaluated Tirzepatide in diverse populations with T2DM, consistently showed superior, dose-dependent reductions in hemoglobin A1c (HbA1c) and body weight when compared against placebo, the selective GLP-1 RA semaglutide, and various basal insulins.[7] A significant proportion of patients treated with higher doses of Tirzepatide achieved normoglycemia (HbA1c <5.7%), a level of glycemic control that challenges traditional treatment goals and suggests a potential for disease modification.[8]

Similarly, the SURMOUNT program in individuals with obesity or overweight demonstrated weight loss of a magnitude previously seen only with bariatric surgery. In the pivotal SURMOUNT-1 trial, participants without T2DM achieved a mean weight reduction of up to 20.9% at 72 weeks, establishing a new ceiling for pharmacological intervention in obesity.[4] Head-to-head trials against semaglutide have confirmed the clinical superiority of Tirzepatide's dual-agonist mechanism in both T2DM (SURPASS-2) and obesity (SURMOUNT-5).[11] Furthermore, positive results from trials in OSA (SURMOUNT-OSA), metabolic dysfunction-associated steatohepatitis (MASH; SYNERGY-NASH), and heart failure with preserved ejection fraction (HFpEF; SUMMIT) underscore its pleiotropic benefits across the spectrum of obesity-related comorbidities.[13]

The safety profile of Tirzepatide is broadly consistent with the GLP-1 RA class, with the most common adverse events being transient, mild-to-moderate gastrointestinal effects that occur primarily during dose escalation.[16] It carries a boxed warning for the risk of thyroid C-cell tumors, based on findings in rodents, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.[18] The long half-life of approximately 5 days supports a convenient once-weekly subcutaneous dosing regimen but necessitates a slow, 4-week dose-escalation schedule to ensure tolerability.[3] Tirzepatide's transformative efficacy and expanding indications position it as a foundational therapy in the field of cardiometabolic medicine.

Molecular Profile and Pharmaceutical Characteristics

Chemical Identity and Structure

Tirzepatide is a synthetic peptide-based therapeutic classified as a biotech drug.[3] Its identity is established by several key identifiers:

• DrugBank ID: DB15171 [3]
• CAS Number: 2023788-19-2 [3]
• Synonyms: LY3298176, GIP/GLP-1 RA [1]

Tirzepatide is a large molecule with the chemical formula C225​H348​N48​O68​ and a molar mass of 4813.527 g·mol−1.[3] It is a linear synthetic peptide composed of 39 amino acids, whose sequence is primarily based on the native human GIP sequence, engineered to confer dual agonism at both GIP and GLP-1 receptors.[2]

The molecular architecture of Tirzepatide is a testament to rational drug design, incorporating several key modifications to optimize its pharmacological properties. These modifications work in concert to achieve a prolonged half-life and potent dual agonism.

1. GIP-Based Backbone: The peptide's primary sequence is an analog of human GIP, which provides the foundation for its potent activity at the GIP receptor.[2]
2. DPP-4 Resistance: The structure incorporates two non-coded amino acid residues, alpha-aminoisobutyric acid (Aib), at positions 2 and 13.[24] Native incretin hormones like GIP and GLP-1 are rapidly degraded and inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4). The substitution with Aib at these positions sterically hinders DPP-4 cleavage, conferring significant resistance to enzymatic degradation and preventing rapid inactivation after administration.[1]
3. Extended Half-Life Moiety: A C20 fatty diacid moiety is conjugated to the epsilon-amino group of the lysine residue at position 20. This conjugation is mediated by a hydrophilic linker composed of a gamma-glutamic acid (γ-Glu) residue and two (2-(2-aminoethoxy)ethoxy)acetic acid (AEEA) units.[1] This long fatty acid chain facilitates high-affinity, reversible binding to circulating plasma albumin.[2]

The combination of these structural features is synergistic. Resistance to DPP-4 degradation prevents immediate enzymatic breakdown, while the strong albumin binding creates a large circulating reservoir of the drug. This reservoir effect minimizes renal filtration and clearance, thereby dramatically extending the molecule's elimination half-life to approximately 5 days.[3] This pharmacokinetic profile is the basis for its convenient and effective once-weekly subcutaneous dosing regimen. This multi-pronged strategy of combining enzymatic resistance with a half-life extension moiety has set a new standard for the development of long-acting peptide therapeutics.

Formulation, Presentation, and Storage

Tirzepatide is formulated as a sterile, preservative-free, clear, and colorless to slightly yellow solution intended for subcutaneous injection.[26] It is commercially available from Eli Lilly and Company in single-dose, pre-filled pens or single-dose vials at a range of strengths to facilitate dose initiation and titration: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, each delivered in a 0.5 mL volume.[16]

For proper storage, Tirzepatide should be refrigerated at a temperature of 2°C to 8°C (36°F to 46°F). It must be stored in its original carton to protect it from light and should not be frozen. If necessary, a single pen or vial can be stored at room temperature, not exceeding 30°C (86°F), for up to 21 days.[28]

In a research or laboratory context, Tirzepatide is typically supplied as a solid white powder with a purity exceeding 98% as determined by High-Performance Liquid Chromatography (HPLC). It is soluble in solvents such as Dimethyl sulfoxide (DMSO) and is stored at -20°C for long-term stability.[24]

Property	Description	Source(s)
Generic Name	Tirzepatide	1
Drug Type	Biotech, Peptide	3
Commercial Names	Mounjaro®, Zepbound®	3
DrugBank ID	DB15171	3
CAS Number	2023788-19-2	3
Other Synonyms	LY3298176, GIP/GLP-1 RA	1
Molecular Formula	C225​H348​N48​O68​	3
Molar Mass	4813.527 g·mol−1	3
Amino Acid Sequence	Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-γ-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2	24
Appearance	Clear, colorless to slightly yellow solution (commercial); White powder (research grade)	26
Administration	Subcutaneous Injection	3
Storage	Refrigerate at 2°C to 8°C (36°F to 46°F); Protect from light	22

Comprehensive Pharmacological Profile

Mechanism of Action: A First-in-Class Dual Incretin Agonist

Tirzepatide is the first approved therapeutic agent that functions as a single-molecule, dual agonist for the receptors of two endogenous incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).[1] This dual agonism, which has led to the coining of the term "twincretin," allows Tirzepatide to integrate and amplify the metabolic benefits of both pathways, resulting in efficacy that surpasses selective GLP-1 RAs.[5]

Both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) are G-protein-coupled receptors (GPCRs) that, upon activation, stimulate adenylyl cyclase and increase intracellular levels of the second messenger cyclic AMP (cAMP).[1] These receptors are expressed in key metabolic tissues, including pancreatic beta-cells, where they enhance glucose-dependent insulin secretion, and in regions of the brain that are critical for appetite regulation.[21] Tirzepatide binds to and activates both of these receptor types.[1] Structural studies have elucidated specific molecular interactions; for example, the glutamic acid at position 3 (Glu3) of Tirzepatide forms a critical ionic bond with arginine residues in both receptors (Arg190 in GLP-1R and Arg183 in GIPR), anchoring the molecule for effective signaling.[1]

While it is a dual agonist, Tirzepatide exhibits a complex and "imbalanced" pharmacological profile. It has a greater binding affinity for the GIP receptor compared to the GLP-1 receptor.[22] Furthermore, at the GLP-1 receptor, it demonstrates biased agonism. It is a full agonist for cAMP generation but only a partial agonist for G-protein coupling and shows very low efficacy for recruiting β-arrestin2.[31] This biased signaling may contribute to its efficacy and tolerability profile, potentially maximizing therapeutic pathways while minimizing those associated with certain adverse effects.

The superior efficacy of Tirzepatide over highly potent selective GLP-1 RAs is not merely an additive effect of two separate actions but a synergistic one, where GIP receptor agonism appears to be the key differentiator in humans. For years, it was believed that individuals with T2DM were largely resistant to the effects of GIP. However, mechanistic studies conducted with Tirzepatide in human pancreatic islets have challenged this dogma. These studies demonstrated that pharmacologically blocking the GIP receptor significantly blunted Tirzepatide's ability to stimulate insulin secretion, whereas blocking the GLP-1 receptor had only a marginal effect.[30] This is in direct contrast to findings in mouse models, where the GLP-1 receptor is the primary driver of its insulinotropic action.[30] This suggests that the primary mechanism for enhanced insulin secretion in humans is driven by potent GIP receptor activation, with the GLP-1 component contributing significantly to its effects on appetite suppression, gastric emptying, and glucagon control. This finding fundamentally reframes the therapeutic potential of GIP in metabolic disease and suggests that GIP is a critical, perhaps even primary, target for achieving maximal glycemic control in T2DM.

Pharmacodynamics: Multi-faceted Metabolic Effects

The dual activation of GIP and GLP-1 receptors by Tirzepatide results in a broad range of coordinated pharmacodynamic effects that improve glucose homeostasis and promote weight loss.[21]

Glycemic Control

• Enhanced Insulin Secretion: Tirzepatide potently stimulates both first- and second-phase insulin secretion from pancreatic beta-cells. This action is glucose-dependent, meaning insulin release is amplified primarily in response to hyperglycemia (e.g., after a meal), which significantly reduces the risk of hypoglycemia compared to insulin secretagogues like sulfonylureas.[2] The synergistic action on both GIP and GLP-1 receptors produces a more robust insulinotropic response than can be achieved with a selective GLP-1 RA alone.[5]
• Glucagon Suppression: By activating GLP-1 receptors on pancreatic alpha-cells, Tirzepatide suppresses the secretion of glucagon, particularly in the postprandial state.[1] Since glucagon's primary role is to stimulate the liver to produce and release glucose, this suppression leads to reduced hepatic glucose output, contributing to lower fasting and postprandial glucose levels.[6]

Weight Management and Energy Homeostasis

• Appetite Regulation and Satiety: Tirzepatide acts centrally on GIP and GLP-1 receptors located in brain regions that control hunger and satiety, such as the hypothalamus.[30] This leads to a significant reduction in appetite, decreased food intake, and a diminished desire for certain foods, often described as a reduction in "food noise".[21] This central effect is a primary driver of its weight loss efficacy.
• Delayed Gastric Emptying: Tirzepatide slows the rate at which food moves from the stomach to the small intestine.[1] This delay has two key benefits: it blunts postprandial glucose excursions by slowing carbohydrate absorption and it prolongs the feeling of fullness after a meal, further contributing to reduced calorie intake.[32]

Other Metabolic Effects

• Improved Insulin Sensitivity: Clinical studies have shown that Tirzepatide significantly improves insulin sensitivity.[5] Post-hoc analyses suggest this effect is not solely a consequence of weight loss, indicating that the dual agonism may have direct effects on peripheral tissues to enhance glucose uptake and utilization.[23]
• Lipid and Adipose Tissue Modulation: Tirzepatide has been shown to increase circulating levels of adiponectin, an adipokine associated with improved insulin sensitivity and anti-inflammatory effects.[5] Furthermore, GIP receptor activation is believed to play a role in improving fat metabolism and promoting energy expenditure, contributing to its robust effect on body weight and composition.[6]

Pharmacokinetics (ADME Profile)

The pharmacokinetic profile of Tirzepatide is characterized by slow absorption and a very long elimination half-life, which underpins its once-weekly dosing schedule.[3]

• Absorption: Following subcutaneous injection, Tirzepatide is absorbed slowly, with a high mean absolute bioavailability of 80%. The time to reach maximum plasma concentration (Tmax​) is broad, ranging from 8 to 72 hours.[5] Steady-state concentrations are achieved after approximately 4 weeks of consistent once-weekly administration.[21]
• Distribution: Tirzepatide exhibits extensive protein binding, with 99% bound to plasma albumin in circulation.[3] This high degree of binding, facilitated by its C20 fatty acid moiety, creates a drug reservoir that limits its availability for metabolism and renal clearance. The mean apparent steady-state volume of distribution ( Vd​) is approximately 10.3 L, indicating that the drug is primarily confined to the vascular and interstitial fluid compartments.[5]
• Metabolism: As a large peptide, Tirzepatide is not metabolized by hepatic cytochrome P450 (CYP) enzymes. Instead, it is cleared through general protein catabolism pathways that occur in various tissues. The primary metabolic routes are proteolytic cleavage of the peptide backbone into smaller peptides and individual amino acids, beta-oxidation of the C20 fatty diacid moiety, and amide hydrolysis.[3]
• Excretion: The resulting metabolites are primarily eliminated via the urine and feces. Intact Tirzepatide is not detectable in either urine or feces, indicating that the parent drug is fully metabolized before excretion.[3] The apparent population mean clearance is low, at approximately 0.061 L/h.[21] The most clinically significant pharmacokinetic parameter is its long elimination half-life of approximately 5 days.[3]

The extended half-life is a key feature that allows for convenient weekly dosing. However, it also has important clinical implications. The long half-life dictates that it takes approximately 4 to 5 weeks (4-5 half-lives) to reach steady-state plasma concentrations after initiating treatment or adjusting the dose. This is the physiological basis for the recommended 4-week dose escalation schedule, which allows the body to gradually adapt to increasing drug concentrations, thereby mitigating the incidence and severity of gastrointestinal side effects.[18] Conversely, this long duration of action means that if a patient experiences significant adverse effects, they will take a considerable time to resolve even after the drug is discontinued. Similarly, the pharmacodynamic effect of delayed gastric emptying is sustained, creating a prolonged window for potential drug-drug interactions with orally administered medications that require rapid absorption or have a narrow therapeutic index.[1]

Parameter	Value / Description	Source(s)
Bioavailability	~80% (subcutaneous)	3
Time to Peak (Tmax​)	8–72 hours	5
Protein Binding	99% (to plasma albumin)	3
Volume of Distribution (Vd​)	~10.3 L	5
Metabolism	Proteolytic cleavage, β-oxidation of fatty acid, amide hydrolysis	3
Elimination Half-Life (t1/2​)	~5 days	3
Clearance	~0.061 L/h	21
Route of Excretion	Urine and feces (as metabolites)	3

Clinical Efficacy in Type 2 Diabetes Mellitus: The SURPASS Program

The efficacy and safety of Tirzepatide for the treatment of T2DM were established in the comprehensive SURPASS phase 3 global clinical development program. This program comprised five pivotal registration trials (SURPASS 1-5) that enrolled over 7,000 patients, evaluating three once-weekly doses of Tirzepatide (5 mg, 10 mg, and 15 mg) across a wide spectrum of the T2DM treatment continuum, from monotherapy in drug-naïve patients to add-on therapy with oral agents and basal insulin.[7] The program consistently demonstrated that Tirzepatide provides superior, dose-dependent improvements in glycemic control and body weight compared to placebo and active comparators, including a selective GLP-1 RA and basal insulins.[8]

SURPASS-1: Monotherapy Efficacy

The SURPASS-1 trial was a 40-week, randomized, double-blind, placebo-controlled study that evaluated Tirzepatide as a monotherapy in 478 adults with T2DM inadequately controlled with diet and exercise alone.[8] Participants, a majority of whom were treatment-naïve, had a mean baseline HbA1c of 7.9% and a mean body weight of 85.9 kg.[35]

Tirzepatide demonstrated statistically significant and clinically meaningful superiority over placebo. Key efficacy outcomes at 40 weeks were [35]:

• Mean HbA1c Reduction: -1.87% (5 mg), -1.89% (10 mg), and -2.07% (15 mg), versus +0.04% for placebo.
• Mean Body Weight Reduction: -7.0 kg (5 mg), -7.8 kg (10 mg), and -9.5 kg (15 mg), versus -0.7 kg for placebo.
• Glycemic Targets: A high percentage of participants achieved the American Diabetes Association's recommended HbA1c target of <7.0%: 87% (5 mg), 92% (10 mg), and 88% (15 mg), compared to only 20% with placebo.

A particularly striking finding was the proportion of participants who achieved normoglycemia, defined as an HbA1c <5.7%. This was achieved by 34% of participants on the 5 mg dose, 31% on the 10 mg dose, and 52% on the 15 mg dose, compared to just 1% in the placebo group.[35]

SURPASS-2: Head-to-Head vs. Semaglutide 1 mg

The SURPASS-2 trial was a 40-week, randomized, open-label, head-to-head study comparing the efficacy and safety of Tirzepatide (5 mg, 10 mg, and 15 mg) with semaglutide 1 mg once weekly in 1,879 patients with T2DM on a background of metformin monotherapy.[8] This trial was critical for establishing Tirzepatide's place relative to the leading selective GLP-1 RA.

Tirzepatide was found to be superior to semaglutide at all three doses for both the primary endpoint of HbA1c reduction and the key secondary endpoint of body weight reduction.[39] Key efficacy outcomes at 40 weeks were [37]:

• Mean HbA1c Reduction: -2.01% (5 mg), -2.24% (10 mg), and -2.30% (15 mg), versus -1.86% for semaglutide 1 mg (based on treatment-regimen estimand). The differences were statistically significant for all doses.
• Mean Body Weight Reduction: -7.6 kg (5 mg), -9.3 kg (10 mg), and -11.2 kg (15 mg), versus -5.7 kg for semaglutide 1 mg. The differences were statistically significant for all doses.
• Glycemic Targets: The percentage of participants achieving an HbA1c <5.7% was substantially higher with Tirzepatide: 27% (5 mg), 40% (10 mg), and 46% (15 mg), compared to 19% with semaglutide.

SURPASS-3 & SURPASS-4: Comparison with Basal Insulins

These trials evaluated Tirzepatide against standard-of-care basal insulin therapies in more advanced T2DM populations.

• SURPASS-3: Compared Tirzepatide to titrated insulin degludec in insulin-naïve patients with T2DM inadequately controlled on oral medications. Tirzepatide demonstrated superior HbA1c and body weight reductions at 52 weeks.[8]
• SURPASS-4: This was the largest and longest trial of the program, enrolling 2,002 patients with T2DM and high cardiovascular (CV) risk. It compared Tirzepatide to titrated insulin glargine over a period of up to 104 weeks.[41] At the primary endpoint of 52 weeks, Tirzepatide was profoundly superior. The 15 mg dose resulted in a mean HbA1c reduction of -2.58% and a mean weight loss of -11.7 kg. In stark contrast, the insulin glargine group had a mean HbA1c reduction of -1.44% and experienced a mean weight gain of 1.9 kg.[42] A post-hoc analysis of SURPASS-4 also revealed important renal benefits, with Tirzepatide treatment significantly slowing the annual rate of estimated glomerular filtration rate (eGFR) decline and reducing the urine albumin-to-creatinine ratio (UACR) compared to insulin glargine, suggesting a potential for kidney protection.[41]

SURPASS-5: Add-on to Insulin Glargine

The SURPASS-5 trial evaluated Tirzepatide as an add-on therapy in 475 patients with T2DM who were inadequately controlled on an existing regimen of titrated basal insulin glargine, with or without metformin.[8] In this 40-week, placebo-controlled study, the addition of Tirzepatide provided significant incremental benefits [5]:

• Mean HbA1c Reduction: -2.11% (5 mg), -2.40% (10 mg), and -2.34% (15 mg), versus -0.86% for placebo.
• Mean Body Weight Change: -5.4 kg (5 mg), -7.5 kg (10 mg), and -8.8 kg (15 mg), versus a gain of +1.6 kg for placebo.

The collective results from the SURPASS program have profound implications for clinical practice. The consistently high rates of patients achieving an HbA1c level below 5.7%—the threshold for pre-diabetes—challenge the conventional T2DM treatment goal of simply reaching an HbA1c below 7.0%.[8] This suggests that for many patients, particularly those with a shorter duration of diabetes, achieving normoglycemia or even disease remission may be a realistic therapeutic objective with early and aggressive intervention using highly effective agents like Tirzepatide.[9] This potential to normalize glycemia, rather than merely control hyperglycemia, represents a fundamental shift in the management of T2DM, moving the therapeutic goalposts from disease management towards disease modification.

Trial (Comparator)	Treatment Arm	Mean Δ HbA1c from Baseline	Mean Δ Body Weight from Baseline	% Pts with HbA1c <7.0%	% Pts with HbA1c <5.7%	Source(s)
SURPASS-1 (Placebo)	Tirzepatide 5 mg	-1.87%	-7.0 kg	87%	34%	35
	Tirzepatide 10 mg	-1.89%	-7.8 kg	92%	31%	35
	Tirzepatide 15 mg	-2.07%	-9.5 kg	88%	52%	35
	Placebo	+0.04%	-0.7 kg	20%	1%	35
SURPASS-2 (Semaglutide 1 mg)	Tirzepatide 5 mg	-2.01%	-7.6 kg	82%	27%	37
	Tirzepatide 10 mg	-2.24%	-9.3 kg	86%	40%	37
	Tirzepatide 15 mg	-2.30%	-11.2 kg	86%	46%	37
	Semaglutide 1 mg	-1.86%	-5.7 kg	79%	19%	37
SURPASS-4 (Insulin Glargine)	Tirzepatide 5 mg	-2.24%	-7.1 kg	81%	23%	42
	Tirzepatide 10 mg	-2.43%	-9.5 kg	88%	33%	42
	Tirzepatide 15 mg	-2.58%	-11.7 kg	91%	43%	42
	Insulin Glargine	-1.44%	+1.9 kg	51%	3%	42
SURPASS-5 (Placebo, add-on to Insulin Glargine)	Tirzepatide 5 mg	-2.11%	-5.4 kg	85%	N/A	5
	Tirzepatide 10 mg	-2.40%	-7.5 kg	90%	N/A	5
	Tirzepatide 15 mg	-2.34%	-8.8 kg	87%	N/A	5
	Placebo	-0.86%	+1.6 kg	34%	N/A	5

Clinical Efficacy in Chronic Weight Management: The SURMOUNT Program

Building on the significant weight loss observed in the SURPASS trials, the SURMOUNT phase 3 clinical development program was designed to specifically evaluate Tirzepatide for chronic weight management in adults with obesity (Body Mass Index ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity.[46] This program has demonstrated a level of efficacy that has redefined the potential of pharmacotherapy for obesity.

SURMOUNT-1: Efficacy in Patients Without Diabetes

The SURMOUNT-1 trial was a landmark 72-week, randomized, double-blind, placebo-controlled study involving 2,539 participants with obesity or overweight who did not have T2DM.[10] The trial met both of its co-primary endpoints, showing statistically significant and clinically unprecedented dose-dependent weight loss compared to placebo.[47]

Key efficacy outcomes at 72 weeks were [10]:

• Mean Percent Body Weight Reduction: -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg), compared to -3.1% with placebo.
• Proportion Achieving ≥5% Weight Loss: 85% (5 mg), 89% (10 mg), and 91% (15 mg), versus 35% with placebo.
• Proportion Achieving ≥20% Weight Loss: 30% (5 mg), 50% (10 mg), and 57% (15 mg), versus only 3.1% with placebo.

The magnitude of weight loss observed, particularly the average reduction of nearly 21% (approximately 24 kg or 52 lbs) at the 15 mg dose, positions Tirzepatide as the first pharmacological agent to produce results that are comparable to those achieved with some forms of bariatric surgery, such as sleeve gastrectomy.[4] This represents a major inflection point in the medical management of obesity, offering a highly effective, non-invasive alternative for patients who may be candidates for, but are hesitant to undergo, surgery. This level of efficacy will likely lead to a profound shift in clinical practice guidelines, elevating pharmacotherapy to a more central and earlier role in the treatment algorithm for severe obesity.

Long-term follow-up data from SURMOUNT-1 extending to 3 years (176 weeks) demonstrated that these weight loss effects were substantial and sustained with continued treatment. At 176 weeks, participants on the 15 mg dose maintained a mean weight loss of 19.7%.[49] Furthermore, among the subset of participants with pre-diabetes at baseline, 3 years of Tirzepatide treatment reduced the risk of progressing to T2DM by 94% compared to placebo, highlighting its profound disease-modifying potential.[49]

SURMOUNT-2: Efficacy in Patients With T2DM

The SURMOUNT-2 trial mirrored the design of SURMOUNT-1 but enrolled adults who had both obesity or overweight and T2DM, a population known to be more resistant to weight loss interventions.[52] Despite this challenge, Tirzepatide demonstrated robust efficacy over 72 weeks [52]:

• Mean Percent Body Weight Reduction: 13.4% (10 mg) and 15.7% (15 mg), compared to 3.3% with placebo.
• This translated to an average weight loss of 29.8 lbs (10 mg) and 34.4 lbs (15 mg), versus 7.0 lbs with placebo.

The trial also showed that the significant weight loss was associated with meaningful improvements in patient-reported health-related quality of life (HRQoL), including physical functioning and psychosocial well-being.[53]

SURMOUNT-4: The Importance of Maintenance Therapy

The SURMOUNT-4 trial was a withdrawal study designed to assess the necessity of continued therapy for weight maintenance.[54] Participants first underwent a 36-week open-label lead-in period with Tirzepatide, during which they achieved significant weight loss. They were then randomized to either continue receiving Tirzepatide or switch to a placebo for an additional 52 weeks.

The results provided definitive evidence that obesity is a chronic, relapsing condition requiring continuous therapy. Participants who continued on Tirzepatide maintained their weight loss and, in many cases, continued to lose additional weight. In contrast, the group that was switched to placebo experienced substantial weight regain over the subsequent year.[55] This outcome powerfully illustrates that Tirzepatide does not "cure" the underlying biology of obesity but rather actively manages it. When the medication is withdrawn, the physiological pressures that promote weight gain re-emerge, leading to relapse. This finding is critical for educating patients, providers, and payers that Tirzepatide and similar agents are not short-term "weight loss drugs" but long-term therapies for the chronic management of obesity.

Trial (Patient Population)	Treatment Arm	Mean % Weight Loss at 72 Weeks	% Pts with ≥5% Loss	% Pts with ≥15% Loss	% Pts with ≥20% Loss	Source(s)
SURMOUNT-1 (Without T2DM)	Tirzepatide 5 mg	-15.0%	85%	48%	30%	10
	Tirzepatide 10 mg	-19.5%	89%	67%	50%	10
	Tirzepatide 15 mg	-20.9%	91%	71%	57%	10
	Placebo	-3.1%	35%	9%	3.1%	10
SURMOUNT-2 (With T2DM)	Tirzepatide 10 mg	-13.4%	N/A	N/A	N/A	52
	Tirzepatide 15 mg	-15.7%	N/A	N/A	N/A	52
	Placebo	-3.3%	N/A	N/A	N/A	52

Head-to-Head Comparative Efficacy: Tirzepatide vs. Semaglutide

To definitively establish the clinical value of Tirzepatide's novel dual-agonist mechanism, direct head-to-head comparative trials against semaglutide—the leading selective GLP-1 RA and previous efficacy benchmark—were essential. The SURPASS-2 and SURMOUNT-5 trials provided this crucial evidence in T2DM and obesity, respectively, demonstrating the clear superiority of the dual-incretin approach.

SURPASS-2: The Diabetes Comparison

The SURPASS-2 trial directly compared Tirzepatide (5, 10, and 15 mg) against the then-standard T2DM dose of semaglutide (1 mg) over 40 weeks in patients with T2DM on background metformin.[37] The results were unequivocal: Tirzepatide was superior to semaglutide across all doses for both glycemic control and weight loss.[39]

• Glycemic Control: At the highest dose (15 mg), Tirzepatide lowered HbA1c by a mean of -2.30% compared to -1.86% for semaglutide 1 mg. This difference of -0.44 percentage points is highly clinically significant.[39]
• Weight Loss: The difference in weight reduction was even more pronounced. The 15 mg Tirzepatide dose led to a mean weight loss of -11.2 kg, nearly double the -5.7 kg loss seen with semaglutide 1 mg.[38]
• Safety and Tolerability: The overall incidence of adverse events was similar between the groups, with gastrointestinal issues being the most common for both drugs. Discontinuation rates due to adverse events were slightly higher in the 10 mg and 15 mg Tirzepatide arms (7.7% and 7.9%, respectively) compared to the semaglutide arm (3.8%), reflecting the greater gastrointestinal burden at higher doses.[38]

SURMOUNT-5: The Obesity Comparison

The SURMOUNT-5 trial was a 72-week, open-label, head-to-head study comparing the maximum tolerated doses of Tirzepatide (10 mg or 15 mg) and semaglutide (1.7 mg or 2.4 mg) in adults with obesity or overweight without T2DM.[12] This trial provided a direct comparison of the two agents at their approved doses for chronic weight management.

The results confirmed the superior efficacy of Tirzepatide [12]:

• Mean Percent Weight Loss: Participants on Tirzepatide achieved a mean weight loss of 20.2% (50.3 lbs), which was 47% greater than the 13.7% (33.1 lbs) mean weight loss observed in the semaglutide group.
• Weight Loss Thresholds: Tirzepatide-treated participants were significantly more likely to achieve higher tiers of weight loss. For instance, 64.6% of those on Tirzepatide lost at least 15% of their body weight, compared to 40.1% of those on semaglutide. Nearly twice as many participants on Tirzepatide (32%) achieved a weight loss of at least 25% compared to semaglutide (16%).

These head-to-head trials provide definitive evidence that the dual GIP/GLP-1 mechanism of Tirzepatide is clinically superior to selective GLP-1 agonism for achieving both glycemic and weight loss endpoints. The magnitude of this superiority is not marginal but substantial and statistically robust. This suggests that the addition of potent GIP receptor agonism to a GLP-1 RA backbone unlocks a new level of synergistic metabolic benefit, impacting factors like insulin sensitivity and fat metabolism in ways that GLP-1 agonism alone cannot. Consequently, Tirzepatide has effectively established a new efficacy ceiling for incretin-based therapies, replacing semaglutide as the new clinical benchmark. This will invariably drive future pharmaceutical development towards multi-agonist molecules and positions Tirzepatide as the first-choice agent when maximal efficacy is the primary therapeutic goal.

Trial	Parameter	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg	Semaglutide	Source(s)
SURPASS-2 (T2DM)	Mean Δ HbA1c	-2.01%	-2.24%	-2.30%	-1.86% (1 mg dose)	39
	Mean Δ Weight	-7.6 kg	-9.3 kg	-11.2 kg	-5.7 kg (1 mg dose)	38
	GI AEs (Nausea)	17.4%	19.2%	22.1%	17.9% (1 mg dose)	38
	Disc. due to AEs	5.1%	7.7%	7.9%	3.8% (1 mg dose)	38
SURMOUNT-5 (Obesity)	Mean % Weight Loss	N/A	-	20.2% (MTD)	13.7% (MTD)	12
	% Pts with ≥15% Loss	N/A	-	64.6% (MTD)	40.1% (MTD)	12
	% Pts with ≥25% Loss	N/A	-	32% (MTD)	16% (MTD)	58
	Δ Waist Circumference	N/A	-	-18.4 cm (MTD)	-13.0 cm (MTD)	12

MTD: Maximum Tolerated Dose (10 mg or 15 mg for Tirzepatide; 1.7 mg or 2.4 mg for Semaglutide)

Efficacy in Novel and Expanded Indications

The profound metabolic benefits of Tirzepatide have prompted its investigation across a range of obesity-related comorbidities. Positive results from phase 2 and phase 3 trials in obstructive sleep apnea (OSA), metabolic dysfunction-associated steatohepatitis (MASH), and heart failure with preserved ejection fraction (HFpEF) are rapidly expanding its therapeutic footprint beyond diabetes and simple weight management.

Obstructive Sleep Apnea (OSA)

Obesity is a primary risk factor for OSA, a condition characterized by repeated episodes of airway obstruction during sleep. The SURMOUNT-OSA clinical trial program evaluated Tirzepatide in adults with moderate-to-severe OSA and obesity.[13] The trials demonstrated that treatment with Tirzepatide led to a statistically significant and clinically meaningful reduction in the apnea-hypopnea index (AHI), which measures the number of breathing disruptions per hour of sleep, compared to placebo. This benefit was observed in patients both with and without concurrent positive airway pressure (PAP) therapy.[13] Based on these robust findings, the U.S. FDA expanded the indication for Zepbound® to include the treatment of moderate-to-severe OSA in adults with obesity.[13]

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

MASH, formerly known as nonalcoholic steatohepatitis (NASH), is a severe form of fatty liver disease characterized by liver inflammation and damage that can progress to cirrhosis and liver failure. It is strongly associated with obesity and T2DM. The phase 2 SYNERGY-NASH trial investigated Tirzepatide in patients with biopsy-confirmed MASH and moderate-to-severe (stage F2 or F3) liver fibrosis.[59]

After 52 weeks of treatment, Tirzepatide met its primary endpoint with high statistical significance. The percentage of participants achieving MASH resolution without any worsening of fibrosis was dose-dependently higher with Tirzepatide compared to placebo [14]:

• Tirzepatide 5 mg: 51.8%
• Tirzepatide 10 mg: 62.8%
• Tirzepatide 15 mg: 73.3%
• Placebo: 13.2%

The trial also met a key secondary endpoint, with over 50% of participants in each Tirzepatide arm achieving at least a one-stage improvement in fibrosis without worsening of MASH, compared to approximately 30% in the placebo group.[14] These results suggest that Tirzepatide can directly address the underlying liver pathology in MASH.

Heart Failure with Preserved Ejection Fraction (HFpEF)

HFpEF is a complex clinical syndrome, particularly prevalent in older adults with obesity, where inflammation and metabolic dysfunction are key pathophysiological drivers. The phase 3 SUMMIT trial evaluated the efficacy of Tirzepatide in patients with HFpEF and obesity.[15]

The trial was positive, demonstrating that Tirzepatide was superior to placebo in improving the primary composite endpoint of cardiovascular death and heart failure-related events (such as hospitalizations or urgent visits) over a median follow-up of 104 weeks.[15] In addition to reducing hard clinical events, Tirzepatide also led to significant improvements in patient-reported outcomes, including symptoms, physical limitations (as measured by the Kansas City Cardiomyopathy Questionnaire), and exercise capacity (as measured by the 6-minute walk distance).[15]

The consistent positive outcomes across OSA, MASH, HFpEF, and renal parameters (from SURPASS-4) reveal that Tirzepatide is not merely a glucose- or weight-lowering agent but a pleiotropic therapy that addresses the entire spectrum of cardiometabolic-renal disease. The common thread linking these disparate conditions is the underlying pathophysiology of obesity, including insulin resistance, systemic inflammation, lipotoxicity, and hemodynamic stress. By targeting the root cause—excess adiposity—and improving core metabolic health, Tirzepatide demonstrates a capacity to modify the course of multiple downstream complications. This positions it as a foundational therapy not just for endocrinologists, but for a wide range of specialists including cardiologists, hepatologists, pulmonologists, and nephrologists.

Safety, Tolerability, and Risk Management

The safety profile of Tirzepatide has been extensively characterized through the SURPASS and SURMOUNT clinical trial programs and is further supported by emerging post-marketing surveillance data. The overall profile is consistent with the GLP-1 RA class, with gastrointestinal adverse events being the most common.

Boxed Warning and Contraindications

In line with other incretin-based therapies, Tirzepatide carries a boxed warning from the U.S. FDA regarding the risk of thyroid C-cell tumors.[16]

• Thyroid C-Cell Tumors: This warning is based on findings in rodent studies, where Tirzepatide caused a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors (adenomas and carcinomas) at clinically relevant exposures. The relevance of this finding to humans is unknown, as no definitive link has been established. However, as a precaution, Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[18] Patients should be counseled on the potential risk and symptoms of thyroid tumors (e.g., a neck mass, dysphagia, dyspnea, persistent hoarseness).
• Hypersensitivity: Tirzepatide is also contraindicated in patients with a history of a serious hypersensitivity reaction to tirzepatide or any of its excipients.[18]

Adverse Event Profile from Clinical Trials

The most frequently reported adverse events in clinical trials were gastrointestinal in nature. These effects were typically mild to moderate in severity, transient, and occurred most commonly during the initial dose-escalation period.[5]

Adverse Event	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg	Placebo	Source(s)
Nausea	24.6%	33.3%	31.0%	9.5%	47
Diarrhea	18.7%	21.2%	23.0%	7.3%	47
Constipation	16.8%	17.1%	11.7%	5.8%	47
Vomiting	8.3%	10.7%	12.2%	1.7%	47
Discontinuation due to AEs	4.3%	7.1%	6.2%	2.6%	47
Serious Adverse Events	6.3%	6.9%	5.1%	6.8%	10

Data from the SURMOUNT-1 trial in patients with obesity/overweight without T2DM.

Serious Adverse Events and Other Warnings

In addition to the boxed warning, the prescribing information for Tirzepatide includes warnings and precautions for several other potential serious adverse reactions [18]:

• Acute Pancreatitis: Cases of acute pancreatitis, including fatal and non-fatal events, have been observed with GLP-1 RAs and Tirzepatide. Patients should be monitored for signs and symptoms (e.g., persistent severe abdominal pain, which may radiate to the back) and the drug should be discontinued if pancreatitis is suspected.[5]
• Acute Gallbladder Disease: Events such as cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported. Rapid weight loss is a known risk factor for these conditions.[5]
• Hypoglycemia: The risk of hypoglycemia is low when Tirzepatide is used as monotherapy or with non-secretagogue agents like metformin. However, the risk is significantly increased when it is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylureas). Dose reduction of the concomitant agent may be necessary.[5]
• Acute Kidney Injury: Severe gastrointestinal adverse reactions can lead to volume depletion and dehydration, which may cause acute kidney injury or worsen pre-existing renal impairment. Patients should be counseled on the importance of maintaining hydration.[5]
• Hypersensitivity Reactions: Serious reactions, including anaphylaxis and angioedema, have been reported. The drug should be discontinued immediately if such a reaction occurs.[16]
• Diabetic Retinopathy Complications: In patients with a history of diabetic retinopathy, rapid improvements in glycemic control have been associated with a temporary worsening of the condition. Patients should be monitored for progression.[5]
• Suicidal Behavior and Ideation: The label for Zepbound® includes a warning to monitor for depression or suicidal thoughts.[18]

Post-Marketing Surveillance and Real-World Evidence

Early analyses of post-marketing data from the FDA Adverse Event Reporting System (FAERS) have largely corroborated the safety profile observed in clinical trials.[67] While these surveillance systems have detected disproportionate reporting signals for expected gastrointestinal events, pancreatitis, and medullary thyroid cancer, direct comparisons suggest that the risk profile of Tirzepatide is similar to, and for some events like diabetic retinopathy and pancreato-biliary disorders, potentially more favorable than, that of the selective GLP-1 RA class.[17]

Drug Interactions and Special Populations

• Oral Medications: By delaying gastric emptying, Tirzepatide can reduce the rate and extent of absorption of concomitantly administered oral medications. This is particularly important for drugs with a narrow therapeutic index (e.g., warfarin) or those requiring rapid absorption for efficacy. Close monitoring is advised.[1]
• Oral Contraceptives: The absorption of oral hormonal contraceptives may be reduced, potentially compromising their efficacy. It is recommended that female patients switch to a non-oral contraceptive method or add a barrier method for 4 weeks after treatment initiation and for 4 weeks following each dose escalation.[28]
• Pregnancy and Lactation: Tirzepatide is not recommended for use during pregnancy, as animal studies suggest a potential for fetal harm. It is unknown if the drug is present in human milk.[3]
• Pediatric Use: The safety and efficacy of Tirzepatide have not been established in patients under 18 years of age.[16]

Regulatory Status and Prescribing Information

Tirzepatide has received regulatory approval from major health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A unique aspect of its marketing in the United States is the use of two distinct brand names for different indications, a strategy that has significant implications for prescribing and insurance coverage.

Global Regulatory Approvals

• United States (FDA): Eli Lilly and Company first received FDA approval for Tirzepatide on May 13, 2022, under the brand name Mounjaro®, as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.[21] Recognizing its profound weight loss effects, the FDA later approved the same active ingredient on November 8, 2023, under the brand name Zepbound® for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.[46] The indication for Zepbound® was subsequently expanded to include the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.[13] It is critical to note that Mounjaro® and Zepbound® are the exact same medication but are approved and marketed for different patient populations, which directly impacts reimbursement pathways.[3]
• European Union (EMA): Tirzepatide was granted marketing authorization by the European Commission on September 15, 2022, under the single brand name Mounjaro®. Initially approved for the treatment of T2DM, its indication was later expanded to include weight management in adults with obesity or overweight with weight-related comorbidities.[34]

Prescribing Information

The dosing and administration protocol for Tirzepatide is identical regardless of the brand name or indication and is designed to maximize tolerability by slowly escalating the dose.

Dosing and Titration

The recommended dose escalation schedule is as follows [5]:

• Starting Dose: Initiate treatment with 2.5 mg injected subcutaneously once weekly for the first 4 weeks. This dose is for treatment initiation only and is not considered a therapeutic dose for glycemic control or weight management.
• Dose Escalation: After 4 weeks on the 2.5 mg dose, increase the dosage to 5 mg once weekly.
• Further Titration: If additional clinical effect is needed, the dosage may be increased in 2.5 mg increments (i.e., to 7.5 mg, 10 mg, 12.5 mg, and 15 mg) after at least 4 weeks on the current dose.

Maintenance and Maximum Dosage

• Mounjaro® (T2DM): The recommended maintenance dosage can be 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg once weekly, based on glycemic needs and tolerability.[19]
• Zepbound® (Weight Management): The recommended maintenance dosages are 5 mg, 10 mg, or 15 mg once weekly. The treating physician should consider treatment response and tolerability when selecting the final maintenance dose.[18]
• Zepbound® (OSA): The recommended maintenance dosages are 10 mg or 15 mg once weekly.[18]
• Maximum Dosage: The maximum recommended dosage for all indications is 15 mg injected subcutaneously once weekly.[5]

Treatment Week(s)	Once-Weekly Subcutaneous Dose	Notes	Source(s)
1–4	2.5 mg	Starting dose for treatment initiation. Not intended for glycemic control or weight management.	18
5–8	5 mg	First therapeutic dose. May be a maintenance dose for T2DM or weight management.	18
9–12	7.5 mg	Increase to this dose if additional efficacy is needed and 5 mg dose is tolerated.	18
13–16	10 mg	May be a maintenance dose for T2DM, weight management, or OSA.	18
17–20	12.5 mg	Increase to this dose if additional efficacy is needed and 10 mg dose is tolerated.	18
21 and beyond	15 mg	Maximum recommended dose. May be a maintenance dose for all indications.	5

Administration and Patient Counseling

• Administration: Tirzepatide is administered via subcutaneous injection into the abdomen, thigh, or upper arm. Patients should be instructed to rotate injection sites with each weekly dose to reduce the risk of local irritation. If a patient also injects insulin, the two injections should be administered at separate sites.[16]
• Missed Dose Protocol: If a dose is missed, it should be administered as soon as possible, provided it is within 4 days (96 hours) of the scheduled dose. If more than 4 days have passed, the patient should skip the missed dose and administer the next dose on the regularly scheduled day. The weekly dosing schedule can then be resumed as normal.[5] The day of weekly administration can be changed if needed, as long as the interval between two doses is at least 3 days (72 hours).[19]

Synthesis and Future Directions

Integrated Analysis: A Paradigm Shift in Metabolic Medicine

The collective evidence from Tirzepatide's extensive development program demonstrates that it is not merely an incremental improvement over existing therapies but a transformative agent that has fundamentally altered the therapeutic landscape for T2DM and obesity. Its dual GIP/GLP-1 receptor agonist mechanism has established a new efficacy ceiling, producing levels of glycemic control and weight loss that were previously thought to be achievable only through surgical intervention.

For T2DM, the ability of Tirzepatide to enable a majority of patients in some trials to achieve normoglycemia (HbA1c <5.7%) represents a paradigm shift. It moves the therapeutic goal beyond simple glycemic "control" and introduces the possibility of disease "remission" as a realistic objective, particularly when initiated early in the disease course. This challenges clinicians and guideline developers to reconsider treatment algorithms, potentially advocating for the earlier use of highly effective agents to maximize long-term metabolic health and prevent complications.

For obesity, the greater than 20% average weight loss seen in the SURMOUNT-1 trial blurs the traditional distinction between medical and surgical management. Tirzepatide now offers a potent, non-invasive alternative that will reshape how severe obesity is treated. The results from the SURMOUNT-4 withdrawal study further reinforce the modern understanding of obesity as a chronic, relapsing disease that requires continuous, long-term pharmacotherapy for sustained benefit, much like hypertension or hyperlipidemia.

Position in Therapy and Clinical Implications

Tirzepatide is positioned to become a foundational therapy for the broad spectrum of interconnected cardiometabolic-renal diseases. The positive trial results in OSA, MASH, and HFpEF, coupled with evidence of renal protection, indicate that its benefits extend far beyond its primary indications. By addressing the root pathophysiological driver of many of these conditions—excess adiposity and metabolic dysregulation—Tirzepatide has the potential to modify the natural history of multiple comorbidities simultaneously.

In clinical practice, the head-to-head data against semaglutide positions Tirzepatide as the agent of choice when the primary goal is to achieve maximal efficacy in either glycemic control or weight reduction. The decision to use Tirzepatide will depend on patient-specific factors, including the severity of hyperglycemia or obesity, the presence of comorbidities, tolerability, and access/cost considerations.

Unanswered Questions and Future Research

Despite the wealth of positive data, several important questions remain, which will be the focus of ongoing and future research:

• Cardiovascular Outcomes: While a meta-analysis of the SURPASS trials showed a favorable trend with a hazard ratio of 0.74 for major adverse cardiovascular events (MACE), the trials were not powered to demonstrate a definitive cardiovascular benefit.[42] The ongoing SURPASS-CVOT trial, which compares Tirzepatide directly against the active comparator dulaglutide, is designed to provide this crucial evidence and is expected to report its findings in 2025.[77]
• Long-Term Safety: While the safety profile to date is reassuring and consistent with the drug class, long-term post-marketing surveillance will be critical to fully characterize the human risk of rare but serious adverse events, such as medullary thyroid carcinoma and pancreatitis.
• Next-Generation Therapies: The success of dual agonism has spurred intense research into multi-agonist molecules. The next frontier includes triple agonists that also target the glucagon receptor, which may offer even greater benefits for weight loss and liver metabolism.
• Health Economics and Access: As a premium-priced therapy, the long-term cost-effectiveness of Tirzepatide is a critical area of study. Demonstrating that its high upfront cost is offset by a reduction in the long-term costs of managing T2DM, obesity, and their myriad complications will be essential for securing broad and equitable access for the vast patient populations who stand to benefit.[78]

Works cited

1. Diabetes Mellitus: Diabetes Mellitus: undefined: Tirzepatide - PDB-101, accessed July 28, 2025, https://pdb101.rcsb.org/global-health/diabetes-mellitus/drugs/incretins/drug/tirzepatide/tirzepatide
2. Tirzepatide | C225H348N48O68 | CID 156588324 - PubChem, accessed July 28, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Tirzepatide
3. Tirzepatide - Wikipedia, accessed July 28, 2025, https://en.wikipedia.org/wiki/Tirzepatide
4. Zepbound vs. Mounjaro: Comparison Guide for Weight Loss and Diabetes Treatment, accessed July 28, 2025, https://www.drugs.com/medical-answers/zepbound-mounjaro-complete-comparison-guide-3578880/
5. Tirzepatide - StatPearls - NCBI Bookshelf, accessed July 28, 2025, https://www.ncbi.nlm.nih.gov/books/NBK585056/
6. How Tirzepatide Works: A Deep Dive into GIP and GLP-1 Dual Agonism, accessed July 28, 2025, https://welllifemedctr.com/how-tirzepatide-works-a-deep-dive-into-gip-and-glp-1-dual-agonism/
7. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/36050763/
8. Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Meaningful Blood Sugar Reductions | American Diabetes Association, accessed July 28, 2025, https://diabetes.org/newsroom/latest-data-from-SURPASS-trials-demonstrate-tirzepatide-provided-blood-sugar-reductions-weight-loss
9. Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials, accessed July 28, 2025, https://diabetesjournals.org/care/article/46/11/1986/153571/Achieving-Normoglycemia-With-Tirzepatide-Analysis
10. Tirzepatide Once Weekly for the Treatment of Obesity - SURMOUNT-1, accessed July 28, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/08/04/15/32/SURMOUNT-1
11. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction - PMC - PubMed Central, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9438179/
12. Tirzepatide: Uses, Dosage, Side Effects & Warnings - Drugs.com, accessed July 28, 2025, https://www.drugs.com/tirzepatide.html
13. FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity - Eli Lilly Investors, accessed July 28, 2025, https://investor.lilly.com/news-releases/news-release-details/fda-approves-zepboundr-tirzepatide-first-and-only-prescription
14. Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks, accessed July 28, 2025, https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-was-superior-placebo-mash-resolution-and-more
15. A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity - SUMMIT - American College of Cardiology, accessed July 28, 2025, https://www.acc.org/latest-in-cardiology/clinical-trials/2024/11/15/15/13/summit
16. Mounjaro® (tirzepatide) Injection: The First and Only GIP and GLP-1 Receptor Agonist Approved for Type 2 Diabetes | Eli Lilly and Company, accessed July 28, 2025, https://www.lilly.com/news/media/media-kits/mounjaro
17. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11473560/
18. Reference ID: 5501094 - accessdata.fda.gov, accessed July 28, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s013lbl.pdf
19. FDA labeling information for Mounjaro - This label may not be the ..., accessed July 28, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
20. Getting Started, Dosing & Prescribing | Mounjaro® (tirzepatide) - Eli Lilly, accessed July 28, 2025, https://mounjaro.lilly.com/hcp/getting-patients-started
21. Tirzepatide: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 28, 2025, https://go.drugbank.com/drugs/DB15171
22. Tirzepatide | GIP and GLP-1 Receptor Agonist | CAS#2023788-19-2 - MedKoo Biosciences, accessed July 28, 2025, https://www.medkoo.com/products/54297
23. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic, accessed July 28, 2025, https://academic.oup.com/jcem/article/106/2/388/6000489
24. CAS 2023788-19-2 Tirzepatide - BOC Sciences, accessed July 28, 2025, https://www.bocsci.com/product/tirzepatide-cas-2023788-19-2-341972.html
25. Tirzepatide | CAS 2023788-19-2 | AdipoGen Life Sciences | Biomol.com, accessed July 28, 2025, https://www.biomol.com/products/chemicals/biochemicals/tirzepatide-ag-cp3-0043-m005
26. Tirzepatide (subcutaneous route) - Side effects & dosage - Mayo Clinic, accessed July 28, 2025, https://www.mayoclinic.org/drugs-supplements/tirzepatide-subcutaneous-route/description/drg-20534045
27. Mounjaro EPAR - tirzepatide - EMA, accessed July 28, 2025, https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
28. Mounjaro, Zepbound (tirzepatide) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed July 28, 2025, https://reference.medscape.com/drug/mounjaro-zepbound-tirzepatide-4000264
29. CAS 2023788-19-2 Tirzepatide (sodium salt) - Alfa Chemistry, accessed July 28, 2025, https://www.alfa-chemistry.com/product/tirzepatide-sodium-salt-cas-2023788-19-2-524302.html
30. Unraveling the Mode of Action of Tirzepatide - Helmholtz Zentrum München, accessed July 28, 2025, https://www.helmholtz-munich.de/en/newsroom/news-all/artikel/unraveling-the-mode-of-action-of-tirzepatide
31. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist - JCI Insight, accessed July 28, 2025, https://insight.jci.org/articles/view/140532
32. Tirzepatide's Mechanism of Action: 7 Ways It Works for Weight Loss, Diabetes, and Sleep Apnea - GoodRx, accessed July 28, 2025, https://www.goodrx.com/classes/gip-receptor-glp-1-receptor-agonists/tirzepatide-mechanism-of-action
33. Tirzepatide: A Double Agonist for Various People Living with Type 2 Diabetes - PMC, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11330428/
34. European Commission grants marketing authorisation for Lilly's Mounjaro® (tirzepatide), the first GIP and GLP-1 receptor agonist for adults with type 2 diabetes in Europe - Eli Lilly, accessed July 28, 2025, https://www.lilly.com/eu/story/european-commission-grants-marketing-authorisation-for-lillys-mounjaro-r
35. Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes, accessed July 28, 2025, https://investor.lilly.com/news-releases/news-release-details/lillys-surpass-1-results-published-lancet-show-tirzepatides
36. Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes - PR Newswire, accessed July 28, 2025, https://www.prnewswire.com/news-releases/lillys-surpass-1-results-published-in-the-lancet-show-tirzepatides-superior-a1c-and-body-weight-reductions-versus-placebo-in-adults-with-type-2-diabetes-301320385.html
37. Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes, accessed July 28, 2025, https://www.lilly.com/en-CA/news/press-releases/21.06.28-SURPASS-2-results-tirzepatide
38. Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes, accessed July 28, 2025, https://investor.lilly.com/news-releases/news-release-details/lillys-surpass-2-results-published-new-england-journal-medicine
39. Tirzepatide-versus-Semaglutide-Once-Weekly-in-Patients-with-Type-2-Diabetes.pdf, accessed July 28, 2025, https://www.sochob.cl/web1/wp-content/uploads/2022/03/Tirzepatide-versus-Semaglutide-Once-Weekly-in-Patients-with-Type-2-Diabetes.pdf
40. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/34170647/
41. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/36152639/
42. Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk - PR Newswire, accessed July 28, 2025, https://www.prnewswire.com/news-releases/tirzepatide-results-published-in-the-lancet-show-superior-a1c-and-body-weight-reductions-compared-to-insulin-glargine-in-adults-with-type-2-diabetes-with-increased-cardiovascular-risk-301402843.html
43. Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk, accessed July 28, 2025, https://investor.lilly.com/node/46101/pdf
44. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/35133415/
45. Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials - PMC, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10620542/
46. FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems | Eli Lilly and Company, accessed July 28, 2025, https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight
47. Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight - PR Newswire, accessed July 28, 2025, https://www.prnewswire.com/news-releases/lillys-surmount-1-results-published-in-the-new-england-journal-of-medicine-show-tirzepatide-achieved-between-16-0-and-22-5-weight-loss-in-adults-with-obesity-or-overweight-301561327.html
48. Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight, accessed July 28, 2025, https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine
49. Tirzepatide for Obesity Treatment and Diabetes Prevention - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/39536238/
50. Tirzepatide Demonstrates 94% Diabetes Reduction, 22% Weight Loss in SURMOUNT-1 Study - Drug Topics, accessed July 28, 2025, https://www.drugtopics.com/view/tirzepatide-demonstrates-94-diabetes-reduction-20-weight-loss-in-surmount-1-study
51. Lilly's tirzepatide cuts diabetes risk, study data show - BioPharma Dive, accessed July 28, 2025, https://www.biopharmadive.com/news/eli-lilly-tirzepatide-diabetes-risk-obesity-study-results/724685/
52. Zepbound (tirzepatide) FDA Approval History - Drugs.com, accessed July 28, 2025, https://www.drugs.com/history/zepbound.html
53. Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12006608/
54. Tirzepatide Completed Phase 3 Trials for Obesity / Overweight Treatment | DrugBank Online, accessed July 28, 2025, https://go.drugbank.com/drugs/DB15171/clinical_trials?conditions=DBCOND0015947%2CDBCOND0015946&phase=3&purpose=treatment&status=completed
55. A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss (SURMOUNT-4) - Lilly Trials, accessed July 28, 2025, https://trials.lilly.com/en-US/trial/268141
56. The effectiveness and value of tirzepatide for type 2 diabetes mellitus, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10373002/
57. First head-to-head study in people living with obesity shows tirzepatide results in around 50% more weight loss than semaglutide | EurekAlert!, accessed July 28, 2025, https://www.eurekalert.org/news-releases/1083453
58. Head-to-Head Trial Compares Weight Loss Drugs | Newsroom | Weill Cornell Medicine, accessed July 28, 2025, https://news.weill.cornell.edu/news/2025/05/head-to-head-trial-compares-weight-loss-drugs
59. Tirzepatide Shows Improvements in MASH Without Worsening Fibrosis - Pharmacy Times, accessed July 28, 2025, https://www.pharmacytimes.com/view/tirzepatide-shows-improvements-in-mash-without-worsening-fibrosis
60. SYNERGY-NASH: Tirzepatide, a GIP/GLP-1 RA, Resolves MASH Without Worsening Fibrosis - HCPLive, accessed July 28, 2025, https://www.hcplive.com/view/synergy-nash-tirzepatide-a-gip-glp-1-ra-resolves-mash-without-worsening-fibrosis
61. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/38856224/
62. Tirzepatide Shows Efficacy Resolving Metabolic Dysfunction-Associated Steatohepatitis without Worsening of Fibrosis - Applied Clinical Trials, accessed July 28, 2025, https://www.appliedclinicaltrialsonline.com/view/tirzepatide-shows-efficacy-resolving-metabolic-dysfunction-associated-steatohepatitis-without-worsening-of-fibrosis
63. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/39555826/
64. Tirzepatide's Safety Profile: A Concierge Doctor's Guide, accessed July 28, 2025, https://conciergemdla.com/blog/tirzepatide-safety-profile/
65. FDA Approves New Medication for Chronic Weight Management, accessed July 28, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
66. Zepbound® (tirzepatide) Injection for Adults with Obesity or OSA, accessed July 28, 2025, https://zepbound.lilly.com/
67. Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes, accessed July 28, 2025, https://www.news-medical.net/news/20240912/Real-world-evidence-highlights-safety-profile-of-tirzepatide-in-managing-type-2-diabetes.aspx
68. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/39141075/
69. Mounjaro: Uses, Dosage, Side Effects & Warnings - Drugs.com, accessed July 28, 2025, https://www.drugs.com/mounjaro.html
70. GLP-1 Agonists - Cleveland Clinic, accessed July 28, 2025, https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
71. Open Letter Regarding the Use of Mounjaro® (tirzepatide) and Zepbound® (tirzepatide) | Eli Lilly and Company - Eli Lilly Investors, accessed July 28, 2025, https://lilly.gcs-web.com/news-releases/news-release-details/open-letter-regarding-use-mounjaror-tirzepatide-and-zepboundr
72. Human medicines European public assessment report (EPAR): Mounjaro, tirzepatide, Date of authorisation: 15/09/2022, Revision: 15, Status, accessed July 28, 2025, https://efim.org/node/141237
73. Lilly's Mounjaro gets EU backing for weight management - FirstWord Pharma, accessed July 28, 2025, https://firstwordpharma.com/story/5799863
74. Mounjaro | European Medicines Agency (EMA), accessed July 28, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
75. Mounjaro (tirzepatide) - EMA - European Union, accessed July 28, 2025, https://www.ema.europa.eu/en/documents/overview/mounjaro-epar-medicine-overview_en.pdf
76. Zepbound (Tirzepatide) Dosages for Weight Loss and Sleep Apnea: Your GoodRx Guide, accessed July 28, 2025, https://www.goodrx.com/zepbound/dosage
77. An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists | JACC, accessed July 28, 2025, https://www.jacc.org/doi/10.1016/j.jacadv.2025.101740
78. www.verywellhealth.com, accessed July 28, 2025, https://www.verywellhealth.com/tirzepatide-vs-semaglutide-8690775#:~:text=A%202023%20review%20of%20data,4
79. Comparison of Semaglutide vs Tirzepatide and Statistical Weight Loss - Pharmko, accessed July 28, 2025, https://www.pharmko.com/blog/comparison-of-semaglutide-vs-tirzepatide-and-statistical-weight-loss
80. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the, accessed July 28, 2025, https://www.jmcp.org/doi/pdf/10.18553/jmcp.2024.30.2.153?download=true